Back

Budget Impact Analysis of Disease-Modifying Therapies for Alzheimer's Disease in Ireland: A Model-Based Analysis

2025-12-30 health economics Title + abstract only
View on medRxiv
Show abstract

BackgroundDisease-modifying therapies (DMTs) for Alzheimers disease, including lecanemab and donanemab, have received regulatory approval in multiple jurisdictions. These therapies require complex diagnostic workup and safety monitoring, raising significant budget impact concerns for healthcare payers. No budget impact analysis specific to Ireland or comparable small European healthcare systems has been published. ObjectiveTo estimate the 5-year budget impact of introducing DMTs for early-stage...

Predicted journal destinations